Frovatriptan
Cephalalgia. 2004 Dec;24(12):1045-8.
Frovatriptan for the treatment of cluster headaches.
Siow HC, Pozo-Rosich P, Silberstein SD.
Jefferson Headache Center, Department of Neurology, Thomas Jefferson University, Philadelphia, PA 19107, USA. siow@juno.com
Cluster headaches both episodic and chronic are some of the most
challenging headaches to treat. Although effective treatments are now
available, some patients continue to be unresponsive to standard
therapy. We present 17 patients from our practice whom we treated
preventively with frovatriptan, a new triptan with a long half-life.
The promising results suggest that this medication may be an useful
addition to our ammaterium against this painful disorder.
PMID: 15566418
Expert Opin Drug Metab Toxicol. 2011 Sep 20.
Pharmacokinetic evaluation of frovatriptan.
Negro A, Lionetto L, Casolla B, Lala N, Simmaco M, Martelletti P.
SourceSapienza University, Regional Referral Headache Center, School of Health Sciences , Department of Medical and Molecular Sciences, Rome , Italy.
Introduction: Migraine is the most common painful neurological disorder, affecting 13% of the general population. Triptans represent a powerful pharmacological tool in acute migraine treatment, however, a significant portion of treated patients cannot have access to this class due to possible adverse affects. Today, a total of seven triptan molecules are available, representing a commonly prescribed migraine treatment. Although there is a need of extensive use of triptans, only 25% of migraine patients are using triptans. Areas covered: This review includes triptans and evidence for the use of frovatriptan. A systematic approach is used to discuss the pharmacodynamic and pharmacokinetic aspects of frovatriptan, considering the emerging data on the clinical efficacy of frovatriptan in the treatment of migraine and cluster headaches. The data were obtained by searching the following key words in MEDLINE: pharmacokinetic, pharmacodynamic, triptans, frovatriptan, migraine, menstrual migraine, relatively to the period 1988 - 2011.
